Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
(2006) In International Journal of Pharmaceutics 314(2006 Mar 8). p.120-126- Abstract
- Several compounds that exhibit a therapeutic effect in experimental models of neurodegenerative diseases have been identified over recent years. Safe and effective drug delivery to the central nervous system is still one of the main obstacles in translating these experimental strategies into clinical therapies. Different approaches have been developed to enable drug delivery in close proximity to the desired site of action. In this review, we describe biodegradable polymeric systems as drug carriers in models of neurodegenerative diseases. Biomaterials described for intracerebral drug delivery are well tolerated by the host tissue and do not exhibit cytotoxic, immunologic, carcinogenic or teratogenic effects even after chronic exposure.... (More)
- Several compounds that exhibit a therapeutic effect in experimental models of neurodegenerative diseases have been identified over recent years. Safe and effective drug delivery to the central nervous system is still one of the main obstacles in translating these experimental strategies into clinical therapies. Different approaches have been developed to enable drug delivery in close proximity to the desired site of action. In this review, we describe biodegradable polymeric systems as drug carriers in models of neurodegenerative diseases. Biomaterials described for intracerebral drug delivery are well tolerated by the host tissue and do not exhibit cytotoxic, immunologic, carcinogenic or teratogenic effects even after chronic exposure. Behavioral improvement and normalization of brain morphology have been observed following treatment using such biomaterials in animal models of Parkinson's, Alzheimer's and Huntington's diseases. Application of these devices for neuroactive drugs is still restricted due to the relatively small volume of tissue exposed to active compound. Further development of polymeric drug delivery systems will require that larger volumes of brain tissue are targeted, with a controlled and sustained drug release that is carefully controlled so it does not cause damage to the surrounding tissue. (c) 2006 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/154735
- author
- Popovic, Natalija LU and Brundin, Patrik LU
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biomaterials, microspheres, neurodegenerative diseases, nanoparticles, biocompatibility, rods
- in
- International Journal of Pharmaceutics
- volume
- 314
- issue
- 2006 Mar 8
- pages
- 120 - 126
- publisher
- Elsevier
- external identifiers
-
- wos:000237905200003
- scopus:33646473959
- ISSN
- 1873-3476
- DOI
- 10.1016/j.ijpharm.2005.09.040
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neuronal Survival (013212041), Basal Ganglia (013212026)
- id
- 30d0ccb6-c634-40bf-a850-1a53a9365377 (old id 154735)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16529886&dopt=Abstract
- date added to LUP
- 2016-04-01 11:57:11
- date last changed
- 2022-04-05 07:28:32
@article{30d0ccb6-c634-40bf-a850-1a53a9365377,
abstract = {{Several compounds that exhibit a therapeutic effect in experimental models of neurodegenerative diseases have been identified over recent years. Safe and effective drug delivery to the central nervous system is still one of the main obstacles in translating these experimental strategies into clinical therapies. Different approaches have been developed to enable drug delivery in close proximity to the desired site of action. In this review, we describe biodegradable polymeric systems as drug carriers in models of neurodegenerative diseases. Biomaterials described for intracerebral drug delivery are well tolerated by the host tissue and do not exhibit cytotoxic, immunologic, carcinogenic or teratogenic effects even after chronic exposure. Behavioral improvement and normalization of brain morphology have been observed following treatment using such biomaterials in animal models of Parkinson's, Alzheimer's and Huntington's diseases. Application of these devices for neuroactive drugs is still restricted due to the relatively small volume of tissue exposed to active compound. Further development of polymeric drug delivery systems will require that larger volumes of brain tissue are targeted, with a controlled and sustained drug release that is carefully controlled so it does not cause damage to the surrounding tissue. (c) 2006 Elsevier B.V. All rights reserved.}},
author = {{Popovic, Natalija and Brundin, Patrik}},
issn = {{1873-3476}},
keywords = {{biomaterials; microspheres; neurodegenerative diseases; nanoparticles; biocompatibility; rods}},
language = {{eng}},
number = {{2006 Mar 8}},
pages = {{120--126}},
publisher = {{Elsevier}},
series = {{International Journal of Pharmaceutics}},
title = {{Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.}},
url = {{http://dx.doi.org/10.1016/j.ijpharm.2005.09.040}},
doi = {{10.1016/j.ijpharm.2005.09.040}},
volume = {{314}},
year = {{2006}},
}